NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes

Progress in Biophysics and Molecular Biology

Volumn 116, Issue 2-3, 2014, Pages 101-112

  Dias, David M ^a   Ciulli, Alessio ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Hit to lead optimization; Multi protein complexes; NMR fragment screening; Protein expression; Protein protein interactions; Structure based lead discovery

Indexed keywords

LIGAND; PROTEIN;

CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

DRUG DISCOVERY; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; PROTEINS;

EID: 84923922070     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2014.08.012     Document Type: Article

References (118)

1. Ayala I., Sounier R., Usé N., Gans P., Boisbouvier J. An efficient protocol for the complete incorporation of methyl-protonated alanine in perdeuterated protein. J.Biomol. NMR 2009, 43:111-119.
2. Baldwin A.J., Kay L.E. NMR spectroscopy brings invisible protein states into focus. Nat. Chem. Biol. 2009, 5:808-814.
3. Barrett P.J., Chen J., Cho M.-K., Kim J.-H., Lu Z., Mathew S., Peng D., Song Y., Van Horn W.D., Zhuang T., Sönnichsen F.D., Sanders C.R. The quiet renaissance of protein nuclear magnetic resonance. Biochemistry 2013, 52:1303-1320.
4. Becattini B., Pellecchia M. SAR by ILOEs: an NMR-based approach to reverse chemical genetics. Chemistry 2006, 12:2658-2662.
5. Blundell T.L. Structure-based drug design. Nature 1996, 384:23-26.
6. Bodenhausen G., Ruben D.J. Natural abundance nitrogen-15 NMR by enhanced heteronuclear spectroscopy. Chem. Phys. Lett. 1980, 69:185-189.
7. Boehr D.D., Nussinov R., Wright P.E. The role of dynamic conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 2009, 5:789-796.
8. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y.J., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L., Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
9. Bonvin A.M., Boelens R., Kaptein R. NMR analysis of protein interactions. Curr. Opin. Chem. Biol. 2005, 9:501-508.
10. Borsi V., Calderone V., Fragai M., Luchinat C., Sarti N. Entropic contribution to the linking coefficient in fragment based drug design: a case study. J.Med. Chem. 2010, 53:4285-4289.
11. Buckley D.L., Gustafson J.L., Van Molle I., Roth A.G., Tae H.S., Gareiss P.C., Jorgensen W.L., Ciulli A., Crews C.M. Small-molecule inhibitors of the interaction between the E3 Ligase VHL and HIF1α. Angew. Chem. Int. Ed. 2012, 51:11463-11467.
12. Buckley D.L., Van Molle I., Gareiss P.C., Tae H.S., Michel J., Noblin D.J., Jorgensen W.L., Ciulli A., Crews C.M. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J.Am. Chem. Soc. 2012, 134:4465-4468.
13. Busche A.E.L., Aranko A.S., Talebzadeh-Farooji M., Bernhard F., Dötsch V., Iwaï H. Segmental isotopic labeling of a central domain in a multidomain protein by protein trans-splicing using only one robust DnaE intein. Angew. Chem. Int. Ed. 2009, 48:6128-6131.
14. Ciulli A., Williams G., Smith A.G., Blundell T.L., Abell C. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J.Med. Chem. 2006, 49:4992-5000.
15. Constantine K.L., Davis M.E., Metzler W.J., Mueller L., Claus B.L. Protein-ligand NOE matching: a high-throughput method for binding pose evaluation that does not require protein NMR resonance assignments. J.Am. Chem. Soc. 2006, 128:7252-7263.
16. Cowburn D., Shekhtman A., Xu R., Ottesen J.J., Muir T.W. Segmental isotopic labeling for structural biological applications of NMR. Methods Mol. Biol. 2004, 278:47-56.
17. Cummings C.G., Hamilton A.D. Disrupting protein-protein interactions with non-peptidic, small molecule α-helix mimetics. Curr. Opin. Chem. Biol. 2010, 14:341-346.
18. 19F NMR-based screening: toward sensitive high-throughput screening with rapid deconvolution. Magn. Reson. Chem. 2012, 50:592-597.
19. Dalvit C., Pevarello P., Tatò M., Veronesi M., Vulpetti A., Sundström M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J.Biomol. NMR 2000, 18:65-68.
20. Dalvit C., Fagerness P.E., Hadden D.T.A., Sarver R.W., Stockman B.J. Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability. J.Am. Chem. Soc. 2003, 125:7696-7703.
21. Dias D.M., Van Molle I., Baud M.G.J., Galdeano C., Geraldes C.F.G.C., Ciulli A. Is NMR fragment screening fine-tuned to assess druggability of protein-protein interactions?. ACS Med. Chem. Lett. 2014, 5:23-28.
22. Diercks T., Coles M., Kessler H. Applications of NMR in drug discovery. Curr. Opin. Chem. Biol. 2001, 5:285-291.
23. Drewry D.H., Macarron R. Enhancements of screening collections to address areas of unmet medical need: an industry perspective. Curr. Opin. Chem. Biol. 2010, 14:289-298.
24. Drysdale M., Brough P. Medicinal chemistry of Hsp90 inhibitors. Curr. Top. Med. Chem. 2008, 8:859-868.
25. Edfeldt F.N.B., Folmer R.H.A., Breeze A.L. Fragment screening to predict druggability (ligandability) and lead discovery success. Drug. Discov. Today 2011, 16:284-287.
26. Fernández C., Jahnke W. New approaches for NMR screening in drug discovery. Drug. Discov. Today 2004, 1:277-283.
27. Frederick K.K., Marlow M.S., Valentine K.G., Wand A.J. Conformational entropy in molecular recognition by proteins. Nature 2007, 448:325-329.
28. Fry D.C. Protein-protein interactions as targets for small molecule drug discovery. Biopolymers 2006, 84:535-552.
29. Fuller J.C., Burgoyne N.J., Jackson R.M. Predicting druggable binding sites at the protein-protein interface. Drug. Discov. Today 2009, 14:155-161.
30. Gretes M., Lim D.C., de Castro L., Jensen S.E., Kang S.G., Lee K.J., Strynadka N.C.J. Insights into positive and negative requirements for protein-protein interactions by crystallographic analysis of the β-lactamase inhibitory proteins BLIP, BLIP-I, and BLP. J.Mol. Biol. 2009, 389:289-305.
31. Griswold I.J., Dahlquist F.W. Bigger is better: megadalton protein NMR in solution. Nat. Struct. Biol. 2002, 9:567-568.
32. Guan J.-Y., Keizers P.H.J., Liu W.-M., Löhr F., Skinner S.P., Heeneman E.A., Schwalbe H., Ubbink M., Siegal G. Small-molecule binding sites on proteins established by paramagnetic NMR spectroscopy. J.Am. Chem. Soc. 2013, 135:5859-5868.
33. Guo C., Tugarinov V. Identification of HN-methyl NOEs in large proteins using simultaneous amide-methyl TROSY-based detection. J.Biomol. NMR 2009, 43:21-30.
34. Hajduk P.J., Greer J. Adecade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug. Discov. 2007, 6:211-219.
35. Hajduk P.J., Dinges J., Schkeryantz J.M., Janowick D., Kaminski M., Tufano M., Augeri D.J., Petros A., Nienaber V., Zhong P., Hammond R., Coen M., Beutel B., Katz L., Fesik S.W. Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. J.Med. Chem. 1999, 42:3852-3859.
36. Hajduk P.J., Gomtsyan A., Didomenico S., Cowart M., Bayburt E.K., Solomon L., Severin J., Smith R., Walter K., Holzman T.F., Stewart A., McGaraughty S., Jarvis M.F., Kowaluk E.A., Fesik S.W. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J.Med. Chem. 2000, 43:4781-4786.
37. Hajduk P.J., Mack J.C., Olejniczak E.T., Park C., Dandliker P.J., Beutel B.A. SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. J.Am. Chem. Soc. 2004, 126:2390-2398.
38. Hajduk P.J., Huth J.R., Fesik S.W. Druggability indices for protein targets derived from NMR-based screening data. J.Med. Chem. 2005, 48:2518-2525.
39. Hansen D.F., Feng H., Zhou Z., Bai Y., Kay L.E. Selective characterization of microsecond motions in proteins by NMR relaxation. J.Am. Chem. Soc. 2009, 131:16257-16265.
40. Harner M.J., Frank A.O., Fesik S.W. Fragment-based drug discovery using NMR spectroscopy. J.Biomol. NMR 2013, 56:65-75.
41. Higueruelo A.P., Schreyer A., Bickerton G.R.J., Pitt W.R., Groom C.R., Blundell T.L. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug. Des. 2009, 74:457-467.
42. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug. Discov. 2002, 1:727-730.
43. Huth J.R., Sun C., Sauer D.R., Hajduk P.J. Utilization of NMR-derived fragment leads in drug design. Meth. Enzymol. 2005, 394:548-571.
44. Hwang T.L., Mori S., Shaka A.J. Application of phase-modulated CLEAN chemical EXchange spectroscopy (CLEANEX-PM) to detect water-protein proton exchange and intermolecular NOEs. J.Am. Chem. Soc. 1997, 119:6203-6204.
45. Hwang T.-L., van Zijl P.C.M., Mori S. Accurate quantitation of water-amide proton exchange rates using the Phase-Modulated CLEAN chemical EXchange (CLEANEX-PM) approach with a Fast-HSQC (FHSQC) detection scheme. J.Biomol. NMR 1998, 11:221-226.
46. Jahnke W. Spin labels as a tool to identify and characterize protein - ligand interactions by NMR spectroscopy. ChemBioChem 2002, 3:167-173.
47. Jahnke W. Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility. J.Biomol. NMR 2007, 39:87-90.
48. Jahnke W., Rüdisser S., Zurini M. Spin label enhanced NMR screening. J.Am. Chem. Soc. 2001, 123:3149-3150.
49. Jencks W.P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U. S. A. 1982, 78:4046-4050.
50. Jubb H., Higueruelo A.P., Winter A., Blundell T.L. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol. Sci. 2012, 33:241-248.
51. Karplus M., Kuriyan J. Molecular dynamics and protein function. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:6679-6685.
52. Kay L.E. Protein dynamics from NMR. Nat. Struct. Biol. 1998, 5. Supplement 513-517.
53. Kay L.E., Torchia D.A., Bax A. Backbone dynamics of proteins as studied by nitrogen-15 inverse detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease. Biochemistry 1989, 28:8972-8979.
54. Kern D., Zuiderweg E. The role of dynamics in allosteric regulation. Curr. Opin. Struct. Biol. 2003, 13:748-757.
55. Krzeminski M., Loth K., Boelens R., Bonvin A.M.J.J. SAMPLEX: automatic mapping of perturbed and unperturbed regions of proteins and complexes. BMC Bioinforma. 2010, 11:51.
56. Kumari S., van der Hoorn R.A. Astructural biology perspective on bioactive small molecules and their plant targets. Curr. Opin. Plant Biol. 2011, 14:480-488.
57. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U. S. A 1999, 96:9997-10002.
58. 15N relaxation rates in perdeuterated proteins by TROSY-based methods. J.Biomol. NMR 2012, 53:209-221.
59. Lepre C.A. Practical aspects of NMR-based fragment screening. Methods Enzymol. 2011, 493:219-239.
60. Li Y., Altorelli N.L., Bahna F., Honig B., Shapiro L., Palmer A.G. Mechanism of E-cadherin dimerization probed by NMR relaxation dispersion. Proc. Natl. Acad. Sci. U. S. A 2013, 110:16462-16467.
61. Lin D., Sze K.H., Cui Y., Zhu G. Clean SEA-HSQC: a method to map solvent exposed amides in large non-deuterated proteins with gradient-enhanced HSQC. J.Biomol. NMR 2002, 23:317-322.
62. Lipari G., Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J.Am. Chem. Soc. 1982, 104:4546-4559.
63. Long D., Marshall C.B., Bouvignies G., Mazhab-Jafari M.T., Smith M.J., Ikura M., Kay L.E. Acomparative CEST NMR study of slow conformational dynamics of small GTPases complexed with GTP and GTP analogues. Angew. Chem. Int. Ed. 2013, 52:10771-10774.
64. Ludwig C., Guenther U.L. Ligand based NMR methods for drug discovery. Front. Biosci. 2009, 14:4565-4574.
65. Mainz A., Religa T.L., Sprangers R., Linser R., Kay L.E., Reif B. NMR spectroscopy of soluble protein complexes at one mega-Dalton and beyond. Angew. Chem. Int. Ed. 2013, 52:8746-8751.
66. Makley L.N., Gestwicki J.E. Expanding the number of "druggable" targets: non-enzymes and protein-protein interactions. Chem. Biol. Drug. Des. 2013, 81:22-32.
67. Mashalidis E.H., Sledź P., Lang S., Abell C. Athree-stage biophysical screening cascade for fragment-based drug discovery. Nat. Protoc. 2013, 8:2309-2324.
68. Mayer M., Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 1999, 38:1784-1788.
69. Mayer M., Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J.Am. Chem. Soc. 2001, 123:6108-6117.
70. Mittermaier A., Kay L.E. New tools provide new insights in NMR studies of protein dynamics. Science 2006, 312:224-228.
71. Mootz H.D. Split inteins as versatile tools for protein semisynthesis. ChemBioChem 2009, 10:2579-2589.
72. Mortenson P.N., Murray C.W. Assessing the lipophilicity of fragments and early hits. J.Comput Aided Mol. Des. 2011, 25:663-667.
73. 15N relaxation dispersion NMR spectroscopy: application to Asn and Gln residues in a cavity mutant of T4 lysozyme. J.Am. Chem. Soc. 2001, 123:967-975.
74. Mund M., Overbeck J.H., Ullmann J., Sprangers R. LEGO-NMR spectroscopy: a method to visualize individual subunits in large heteromeric complexes. Angew. Chem. Int. Ed. 2013, 52:11401-11405.
75. Muona M., Aranko A.S., Raulinaitis V., Iwaï H. Segmental isotopic labeling of multi-domain and fusion proteins by protein trans-splicing invivo and invitro. Nat. Protoc. 2010, 5:574-587.
76. Murray C.W., Verdonk M.L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J.Comput Aided Mol. Des. 2002, 16:741-753.
77. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug. Discov. 2006, 5:596-613.
78. Neudecker P., Lundström P., Kay L.E. Relaxation dispersion NMR spectroscopy as a tool for detailed studies of protein folding. Biophys. J. 2009, 96:2045-2054.
79. Nooren I.M.A., Thornton J.M. Diversity of protein-protein interactions. EMBO J. 2003, 22:3486-3492.
80. Núñez S., Venhorst J., Kruse C.G. Target-drug interactions: first principles and their application to drug discovery. Drug. Discov. Today 2012, 17:10-22.
81. Ollerenshaw J.E., Tugarinov V. Methyl TROSY: explanation and experimental verification. Magn. Reson. Chem. 2003, 41:843-852.
82. Oost T.K., Sun C., Armstrong R.C., Al-Assaad A.-S., Betz S.F., Deckwerth T.L., Ding H., Elmore S.W., Meadows R.P., Olejniczak E.T., Oleksijew A., Oltersdorf T., Rosenberg S.H., Shoemaker A.R., Tomaselli K.J., Zou H., Fesik S.W. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J.Med. Chem. 2004, 47:4417-4426.
83. Palmer A.G. NMR characterization of the dynamics of biomacromolecules. Chem. Rev. 2004, 104:3623-3640.
84. Pellecchia M., Meininger D., Shen A.L., Jack R., Kasper C.B., Sem D.S. SEA-TROSY (solvent exposed amides with TROSY): a method to resolve the problem of spectral overlap in very large proteins. J.Am. Chem. Soc. 2001, 123:4633-4634.
85. Pellecchia M., Sem D.S., Wüthrich K. NMR in drug discovery. Nat. Rev. Drug. Discov. 2002, 1:211-219.
86. Pellecchia M., Bertini I., Cowburn D., Dalvit C., Giralt E., Jahnke W., James T.L., Homans S.W., Kessler H., Luchinat C., Meyer B., Oschkinat H., Peng J., Schwalbe H., Siegal G. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug. Discov. 2008, 7:738-745.
87. Pervushin K., Riek R., Wider G., Wüthrich K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. U. S. A 1997, 94:12366-12371.
88. Petros A.M., Huth J.R., Oost T., Park C.-M., Ding H., Wang X., Zhang H., Nimmer P., Mendoza R., Sun C., Mack J., Walter K., Dorwin S., Gramling E., Ladror U., Rosenberg S.H., Elmore S.W., Fesik S.W., Hajduk P.J. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg. Med. Chem. Lett. 2010, 20:6587-6591.
89. Rees D.C., Congreve M., Murray C.W., Carr R. Fragment-based lead discovery. Nat. Rev. Drug. Discov. 2004, 3:660-672.
90. Roberts G.C.K. Applications of NMR in drug discovery. Drug. Discov. Today 2000, 5:230-240.
91. Sanchez-Pedregal V.M., Reese M., Meiler J., Blommers M.J., Griesinger C., Carlomagno T. The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. Angew. Chem. Int. Ed. 2005, 44:4127-4175.
92. Sattler M., Fesik S.W. Use of deuterium labeling in NMR: overcoming a sizeable problem. Structure 1996, 4:1245-1249.
93. Showalter S.A., Brüschweiler R. Validation of molecular dynamics simulations of biomolecules using NMR spin relaxation as benchmarks: application to the AMBER99SB force field. J.Chem. Theory Comput. 2007, 3:961-975.
94. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
95. Sledz P., Silvestre H.L., Hung A.W., Ciulli A., Blundell T.L., Abell C. Optimization of the interligand overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. J.Am. Chem. Soc. 2010, 132:4544-4545.
96. Sledź P., Abell C., Ciulli A. Ligand-observed NMR in fragment-based approaches. NMR of Biomolecules: Towards Mechanistic Systems Biology 2012, 264-280. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
97. Smith M.C., Gestwicki J.E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med. 2012, 14:e16.
98. Stone M.J. NMR relaxation studies of the role of conformational entropy in protein stability and ligand binding. Acc. Chem. Res. 2001, 34:379-388.
99. Stukalov A., Superti-Furga G., Colinge J. Deconvolution of targeted protein-protein interaction maps. J.Proteome Res. 2012, 11:4102-4109.
100. Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., Lee T., Rossanese O.W., Fesik S.W. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. 2012, 51:6140-6143.
101. Surade S., Blundell T.L. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 2012, 19:42-50.
102. Takahashi H., Nakanishi T., Kami K., Arata Y., Shimada I. Anovel NMR method for determining the interfaces of large protein-protein complexes. Nat. Struct. Biol. 2000, 7:220-223.
103. Thangudu R.R., Bryant S.H., Panchenko A.R., Madej T. Modulating protein-protein interactions with small molecules: the importance of binding hotspots. J.Mol. Biol. 2012, 415:443-453.
104. Thiel P., Kaiser M., Ottmann C. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?. Angew. Chem. Int. Ed. 2012, 51:2012-2018.
105. Tugarinov V., Kay L.E. An isotope labeling strategy for methyl TROSY spectroscopy. J.Biomol. NMR 2004, 28:165-172.
106. 1H-13C NMR spectroscopy. J.Am. Chem. Soc. 2004, 126:4921-4925.
107. 1H-13C NOE spectroscopy using methyl-TROSY, sparse data acquisition, and multidimensional decomposition. J.Am. Chem. Soc. 2005, 127:2767-2775.
108. Tzeng S.-R., Kalodimos C.G. Protein activity regulation by conformational entropy. Nature 2012, 488:236-240.
109. Vallurupalli P., Bouvignies G., Kay L.E. Increasing the exchange time-scale that can be probed by CPMG relaxation dispersion NMR. J.Phys. Chem. B 2011, 115:14891-14900.
110. Van Molle I., Thomann A., Buckley D.L., So E.C., Lang S., Crews C.M., Ciulli A. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:Hypoxia inducible factor 1α protein-protein interface. Chem. Biol. 2012, 19:1300-1312.
111. Vanwetswinkel S., Heetebrij R.J., van Duynhoven J., Hollander J.G., Filippov D.V., Hajduk P.J., Siegal G. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem. Biol. 2005, 12:207-216.
112. Velyvis A., Schachman H.K., Kay L.E. Application of methyl-TROSY NMR to test allosteric models describing effects of nucleotide binding to aspartate transcarbamoylase. J.Mol. Biol. 2009, 387:540-547.
113. Wang C., Grey J., M., G, Palmer A. CPMG sequences with enhanced sensitivity to chemical exchange. J.Biomol. NMR 2001, 21:361-366.
114. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
115. Williamson M.P. Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc. 2013, 73:1-16.
116. Woodhead A.J., Angove H., Carr M.G., Chessari G., Congreve M., Coyle J.E., Cosme J., Graham B., Day P.J., Downham R., Fazal L., Feltell R., Figueroa E., Frederickson M., Lewis J., McMenamin R., Murray C.W., O'Brien M.A., Parra L., Patel S., Phillips T., Rees D.C., Rich S., Smith D.-M., Trewartha G., Vinkovic M., Williams B., Woolford A.J. Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J.Med. Chem. 2010, 53:5956-5969.
117. Zhu Z., Sun Z.-Y., Ye Y., Voigt J., Strickland C., Smith E.M., Cumming J., Wang L., Wong J., Wang Y.-S., Wyss D.F., Chen X., Kuvelkar R., Kennedy M.E., Favreau L., Parker E., McKittrick B.A., Stamford A., Czarniecki M., Greenlee W., Hunter J.C. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I-inhibitor design and validation. J.Med. Chem. 2010, 53:951-965.
118. Zorn J.A., Wells J.A. Turning enzymes on with small molecules. Nat. Chem. Biol. 2010, 6:179-188.